Anaphylaxis resident survival guide: Difference between revisions
No edit summary |
|||
Line 1: | Line 1: | ||
__NOTOC__ | __NOTOC__ | ||
{{CMG}}; {{VB}} | {{CMG}}; {{VB}} | ||
==Definition== | ==Definition== | ||
Line 7: | Line 6: | ||
==Causes== | ==Causes== | ||
===Life Threatening Causes=== | ===Life Threatening Causes=== | ||
Line 31: | Line 29: | ||
:* Gastrointestinal manifestations | :* Gastrointestinal manifestations | ||
♦ Reduced blood pressure after exposure to a known allergen. | ♦ Reduced blood pressure after exposure to a known allergen. | ||
==Management== | |||
Shown below is an algorithm summarizing the approach to <nowiki>[[Anaphylaxis]]</nowiki>. | |||
{{familytree/start |summary=PE diagnosis Algorithm.}} | |||
{{familytree | | | | | | | | A01 |A01=<div style="float: left; text-align: left; height: 30 em; width: 30 em ">'''Characterize the symptoms & signs:''' <br> Skin, subcutaneous tissue and mucosa: <br> ❑ Flushing, itching, urticaria, angioedema, rash, piloerection <br> ❑ Periorbital itching, erythema and edema; conjunctival erythema, tearing <br> | |||
---- | |||
Respiratory: <br> ❑ Nasal itching, congestion, rhinorrhea, sneezing <br> ❑ Throat itching and tightness, dysphonia, hoarseness, stridor, dry staccato cough <br> ❑ Tachypnea, dyspnea,chest tightness, wheezing/bronchospasm <br> ❑ Cyanosis <br> ❑ Respiratory arrest <br> | |||
---- | |||
Gastrointenstinal: <br> ❑ Pain, nausea, vomiting, diarrhea <br> | |||
---- | |||
Cardiovascular: <br> ❑ Chest pain, tachycardia, palpitations <br> ❑ Hypotension, feeling faint <br> ❑ shock <br> ❑ Cardiac arrest <br> | |||
---- | |||
Central nervous system: <br> ❑ Anxiety, irritability <br> ❑ Throbbing headache <br> ❑ Altered vision and mental status </div>}} | |||
{{familytree | | | | | | | | |!| | | | | | | | }} | |||
{{familytree | | | | | | | | B01 | | | | | | | |B01=<div style="float: left; text-align: left ">'''Consider alternative diagnosis:''' <br> ❑ Acute asthma <br> ❑ Anxiety/Panic attack <br> ❑ Syncope </div>}} | |||
{{familytree | | | | | | | | |!| | | | | | }} | |||
{{familytree | | | | | | | | C01 | | | | | |C01=Remove patient from exposure/trigger }} | |||
{{familytree | | | | | | | | |!| | | | | | }} | |||
{{familytree | | | | | | | | D01 | | | | | |D01=<div style="float: left; text-align: left">Do all 3 simultaneously <br> ❑ Call for help <br> ❑ '''Inject aqueous epinephrine (adrenaline) IM in the mid-anterolateral aspect of the thigh, 0.01 mg/kg of a 1:1,000 (1 mg/mL) solution''' <br>Maximum dose 0.5 mg (adult) or 0.3 mg (child) <br> Record the time of the dose and repeat it in 5-10 minutes, if needed or <br> ❑ Intravenous epinephrine: In patients with hypotension/cardiorespiratory arrest and those not responding <br> | |||
: 1:100,000 solution of epinephrine (0.1 mg [1 ml of 1:1000] in 100 ml saline) intravenously by infusion pump at an initial rate of 30-100 ml/hr (5-15 mg/min) <br> Titrate based on clinical response or epinephrine side effects <br> | |||
❑ Place patient on back/comfortable position; elevate legs</div> }} | |||
{{familytree | | | | | | | | |!| | | | | | | }} | |||
{{familytree | | | | E02 |-| E01 | | | | | | | |E01=<div style="float: left; text-align: left"> Patient has one of the following? <br> ❑ Respiratory distress <br> ❑ Recieved repeated doses of epinephrine <br> ❑ Asthma/other respiratory disease <br> ❑ Co-existing cardiovascular disease </div> |E02=Yes}} | |||
{{familytree | | | | |!| | | |!| | | | | | | | }} | |||
{{familytree | | | | F01 | | F02 | | | | | | |F01= ❑ Give high flow supplemental oxygen (6-8 L/min) |F02=No }} | |||
{{familytree | | | | |!| | | |!| | | | | | | | }} | |||
{{familytree | | | | |`|-|-| G01 |-| G02 | | | |G01=Patient hypotensive despite epinephrine? |G02=Yes }} | |||
{{familytree | | | | | | | | |!| | | |!| | | | }} | |||
{{familytree | | | | | | | | H01 | | H02 | | |H01=No |H02=<div style="float: left; text-align: left"> ❑ Establish IV access <br> ❑ Give 1-2 litres of 0.9% saline rapidly, 5-10 ml/Kg in first 5-10 mins <br> ❑ Give vasopressors (dopamine) 400mg in 500ml of 5% dextrose at 2-20 mg/kg/min to maintain a target systolic BP > 90 mm Hg </div> }} | |||
{{familytree | | | | | | | | |!| | | |!| | | | }} | |||
{{familytree | | | | | | | | I01 |-|-|'| | | |I01=<div style="float: left; text-align: left"> Secondary therapy after epinephrine '''(evidence not clear)''' <br> H1 antihistaminics: <br> ❑ Diphenhydramine IM or slow intravenous infusion - 25 to 50 mg in adults, and 1 mg/kg up to 50 mg in children | |||
---- | |||
H2 antihistaminics: <br> ❑ Ranitidine - 1 mg/kg in adults, and 12.5 to 50 mg in children IV or IM </div>}} | |||
{{familytree | | | | | | | | |!| | | | | | | | }} | |||
{{familytree | | | | | | | | J01 | | | | | | |J01=<div style="float: left; text-align: left"> ❑ Observe the patient for biphasic anaphylaxis <br> | |||
: Total period of observation depends on <br> a) clinical condition <br> b) patients access to emergency care setting from home <br> | |||
❑ Provide auto-injectable epinephrine and action plan for future events at discharge </div> }} | |||
{{familytree/end}} | |||
==References== | ==References== |
Revision as of 14:30, 17 January 2014
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Vidit Bhargava, M.B.B.S [2]
Definition
An acute, severe, potentially life threatening type 1 hypersensitivity reaction, following repeated exposure to an allergen to which an individual is already sensitised.
Causes
Life Threatening Causes
Any of the factors precipitating anaphylaxis can be life threatening.
- Food: Peanuts, Tree nuts, walnuts, pecans, milk, soyabean, wheat, eggs, pistachios, filberts, cashews, almonds, etc.
- Shellfish: crab, crayfish, prawns, shrimp, lobster, etc.
- Medications: Penicillin, Sulfa antibiotics, Allopurinol, and many other drugs
- Diagnostic materials: IV contrast material and dyes
- Insect venom: including bees, wasps, ants
- Natural rubber latex
- Idiopathic/ Coital anaphylaxis
Diagnostic Criteria
It is diagnosed with one of the following criteria:[1]
♦ Acute onset of a reaction (mins to hours) involving skin, mucous membrane or both. Additionally including atleast one of the following:
- Respiratory compromise or
- Cardiovascular compromise/Evidence of end organ dysfunction.
♦ 2 or more of the following in a patient known to come in contact with an established allergen:
- Skin/mucosal tissue involvement
- Respiratory compromise
- Reduced blood pressure
- Gastrointestinal manifestations
♦ Reduced blood pressure after exposure to a known allergen.
Management
Shown below is an algorithm summarizing the approach to [[Anaphylaxis]].
Characterize the symptoms & signs: Skin, subcutaneous tissue and mucosa: ❑ Flushing, itching, urticaria, angioedema, rash, piloerection ❑ Periorbital itching, erythema and edema; conjunctival erythema, tearing Respiratory: Gastrointenstinal: Cardiovascular: Central nervous system: ❑ Anxiety, irritability ❑ Throbbing headache ❑ Altered vision and mental status | |||||||||||||||||||||||||||||||||
Consider alternative diagnosis: ❑ Acute asthma ❑ Anxiety/Panic attack ❑ Syncope | |||||||||||||||||||||||||||||||||
Remove patient from exposure/trigger | |||||||||||||||||||||||||||||||||
Do all 3 simultaneously ❑ Call for help ❑ Inject aqueous epinephrine (adrenaline) IM in the mid-anterolateral aspect of the thigh, 0.01 mg/kg of a 1:1,000 (1 mg/mL) solution Maximum dose 0.5 mg (adult) or 0.3 mg (child) Record the time of the dose and repeat it in 5-10 minutes, if needed or ❑ Intravenous epinephrine: In patients with hypotension/cardiorespiratory arrest and those not responding
| |||||||||||||||||||||||||||||||||
Yes | Patient has one of the following? ❑ Respiratory distress ❑ Recieved repeated doses of epinephrine ❑ Asthma/other respiratory disease ❑ Co-existing cardiovascular disease | ||||||||||||||||||||||||||||||||
❑ Give high flow supplemental oxygen (6-8 L/min) | No | ||||||||||||||||||||||||||||||||
Patient hypotensive despite epinephrine? | Yes | ||||||||||||||||||||||||||||||||
No | ❑ Establish IV access ❑ Give 1-2 litres of 0.9% saline rapidly, 5-10 ml/Kg in first 5-10 mins ❑ Give vasopressors (dopamine) 400mg in 500ml of 5% dextrose at 2-20 mg/kg/min to maintain a target systolic BP > 90 mm Hg | ||||||||||||||||||||||||||||||||
Secondary therapy after epinephrine (evidence not clear) H1 antihistaminics: ❑ Diphenhydramine IM or slow intravenous infusion - 25 to 50 mg in adults, and 1 mg/kg up to 50 mg in children H2 antihistaminics: ❑ Ranitidine - 1 mg/kg in adults, and 12.5 to 50 mg in children IV or IM | |||||||||||||||||||||||||||||||||
❑ Observe the patient for biphasic anaphylaxis
| |||||||||||||||||||||||||||||||||
References
- ↑ Sampson, HA.; Muñoz-Furlong, A.; Campbell, RL.; Adkinson, NF.; Bock, SA.; Branum, A.; Brown, SG.; Camargo, CA.; Cydulka, R. (2006). "Second symposium on the definition and management of anaphylaxis: summary report--Second National Institute of Allergy and Infectious Disease/Food Allergy and Anaphylaxis Network symposium". J Allergy Clin Immunol. 117 (2): 391–7. doi:10.1016/j.jaci.2005.12.1303. PMID 16461139. Unknown parameter
|month=
ignored (help)